Hana tests targeted chemotherapy agent in patients with advanced solid tumors

By Elaine Rigoli

Tampa, Fla., Aug. 3 - Hana Biosciences Inc. has started a phase 1 clinical study of sphingosome encapsulated vinorelbine in patients with advanced solid tumors.

Hana said it is developing this compound for patients with non-small cell lung cancer and breast cancer, among others.

The study is being conducted at the Cancer Therapy and Research Center in San Antonio and McGill University in Montreal.

"This trial affirms Hana Biosciences' commitment to the continued advancement of promising product candidates with the potential to improve patient care. We believe this novel product may allow for improved delivery and pharmaceutical attributes of vinorelbine, a well-established therapy for lung and breast cancer," senior vice president and chief medical officer Gregory Berk said in a news release.

Hana is a South San Francisco, Calif.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.